Kliniske forsøg har vist, at selv om hyppigheden af lymfom var større hos Kineret - behandlede patienter end den forventede hyppighed hos baggrundspopulationen, svarer forekomsten til de hyppigheder, der generelt rapporteres hos RA- patienter.
In clinical trials, whilst patients treated with Kineret had a higher incidence of lymphoma than the expected rate in the general population, this rate is consistent with rates reported in general for RA patients.